Why insider trading matters?

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

- Peter Lynch
Adaptimmune Therapeutics PLC (ADAP)
Sector: Healthcare; Industry: Biotechnology

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company has a strategic collaboration and license agreement with GSK to research, develop, and commercialize NY-ESO T-cell therapy; and collaboration agreement with Noile-Immune Biotech Inc. to develop SPEAR T-cells in combination with Noile-Immune's PRIME technology. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.


Trade Date Insider Title Buy/Sell #Shares Price Value Option
2021-01-19 Norry Elliot Chief Medical Officer Sell 2,111 $5.67 $11,968 No
2021-01-19 Lunger John Chief Patient Supply Officer Sell 4,358 $5.67 $24,708 No
2021-01-19 Rawcliffe Adrian Chief Executive Officer Sell 9,879 $5.67 $56,009 No
2021-01-12 Bertrand William C JR Chief Operating Officer Sell 2,234 $6.15 $13,744 No
2021-01-12 Lunger John Chief Patient Supply Officer Sell 1,058 $6.15 $6,509 No
2021-01-12 Norry Elliot Chief Medical Officer Sell 841 $6.15 $5,174 No
2021-01-12 Rawcliffe Adrian Chief Executive Officer Sell 2,707 $6.15 $16,654 No
2021-01-04 Lunger John Chief Patient Supply Officer Sell 1,065 $5.33 $5,674 No
2021-01-04 Bertrand William C JR Chief Operating Officer Sell 3,499 $5.33 $18,642 No
2021-01-04 Norry Elliot Chief Medical Officer Sell 845 $5.33 $4,502 No
2021-01-04 Rawcliffe Adrian Chief Executive Officer Sell 4,967 $5.33 $26,464 No
2020-12-14 Wood Gavin Chief Financial Officer Buy 24,000 $0.69 $16,550 No
2020-12-14 Bertrand William C JR Chief Operating Officer Buy 207,000 $0.69 $143,824 No
2020-09-01 Rawcliffe Adrian Chief Executive Officer Sell 2,776 $8.51 $23,637 No
2020-08-03 Lunger John Chief Patient Supply Officer Sell 4,823 $9.25 $44,613 No
2020-08-03 TAYTON-MARTIN HELEN KATRINA Chief Business Officer Sell 200,000 $8.74 $1,748,180 No
2020-08-03 Rawcliffe Adrian Chief Executive Officer Sell 2,788 $9.25 $25,789 No
2020-06-29 Wood Gavin Chief Financial Officer Buy 33,000 $1.62 $53,460 No
2020-06-09 Alleva Lawrence M Director Buy 12,900 $1.89 $24,381 No
2020-05-29 Noble James Director Sell 500,000 $9.33 $4,666,000 No
2020-01-24 Sonsini Peter W. 10%-Owner Buy 7,500,000 $0.67 $5,000,250 No
2020-01-24 SANDELL SCOTT D 10%-Owner Buy 7,500,000 $0.67 $5,000,250 No
2020-01-24 MOTT DAVID M 10%-Owner, Director Buy 7,500,000 $0.67 $5,000,250 No
2020-01-24 Florence Anthony A. Jr. 10%-Owner Buy 7,500,000 $0.67 $5,000,250 No
2020-01-24 Behbahani Ali Director Buy 7,500,000 $0.67 $5,000,250 No
2020-01-24 BASKETT FOREST 10%-Owner Buy 7,500,000 $0.67 $5,000,250 No
2020-01-14 Norry Elliot Chief Medical Officer Sell 911 $5.13 $4,678 No
2020-01-14 Bertrand William C JR Chief Operating Officer Sell 2,397 $5.13 $12,308 No
2020-01-13 TAYTON-MARTIN HELEN KATRINA Chief Business Officer Sell 100,000 $4.50 $450,000 No
2020-01-14 Lunger John Chief Patient Supply Officer Sell 1,144 $5.13 $5,874 No

Insider Smart

PROSPECT CAPITAL CORP (PSEC) - PSEC is the 2nd most bought stock of the past 90 days by insiders, CEO seems very confident about the company.

Insider Smart

Enphase Energy, Inc (ENPH) - Watch for CEO Kothandaraman Badrinarayanan and CFO Branderiz Eric, their trading have a good pattern you can't miss, very well timed buy low and sell high.